AU2015314980A1 - Targeting K-Ras-mediated signaling pathways and malignancy by anti-hLIF antibodies - Google Patents

Targeting K-Ras-mediated signaling pathways and malignancy by anti-hLIF antibodies Download PDF

Info

Publication number
AU2015314980A1
AU2015314980A1 AU2015314980A AU2015314980A AU2015314980A1 AU 2015314980 A1 AU2015314980 A1 AU 2015314980A1 AU 2015314980 A AU2015314980 A AU 2015314980A AU 2015314980 A AU2015314980 A AU 2015314980A AU 2015314980 A1 AU2015314980 A1 AU 2015314980A1
Authority
AU
Australia
Prior art keywords
lif
ras
cancer
agent
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2015314980A
Other languages
English (en)
Inventor
Frank Mccormick
Man-Tzu WANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Publication of AU2015314980A1 publication Critical patent/AU2015314980A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epoxy Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
AU2015314980A 2014-09-10 2015-09-10 Targeting K-Ras-mediated signaling pathways and malignancy by anti-hLIF antibodies Abandoned AU2015314980A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462048770P 2014-09-10 2014-09-10
US62/048,770 2014-09-10
PCT/US2015/049461 WO2016040657A1 (en) 2014-09-10 2015-09-10 TARGETING K-RAS-MEDIATED SIGNALING PATHWAYS AND MALIGNANCY BY ANTI-hLIF ANTIBODIES

Publications (1)

Publication Number Publication Date
AU2015314980A1 true AU2015314980A1 (en) 2017-03-02

Family

ID=55459579

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015314980A Abandoned AU2015314980A1 (en) 2014-09-10 2015-09-10 Targeting K-Ras-mediated signaling pathways and malignancy by anti-hLIF antibodies

Country Status (7)

Country Link
US (1) US20170247446A1 (enExample)
EP (1) EP3191129A4 (enExample)
JP (1) JP2017527582A (enExample)
CN (1) CN106687134A (enExample)
AU (1) AU2015314980A1 (enExample)
CA (1) CA2958685A1 (enExample)
WO (1) WO2016040657A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3173483A1 (en) * 2015-11-27 2017-05-31 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Agents for the treatment of diseases associated with undesired cell proliferation
CN109069211B (zh) 2016-01-26 2022-04-29 网络牙科(美国)公司 自动牙科治疗系统
US10583191B2 (en) 2016-12-19 2020-03-10 Mosaic Biomedicals Slu Antibodies against LIF and uses thereof
SI3555132T1 (sl) 2016-12-19 2024-04-30 Medimmune Limited Protitelesa proti LIF in njihove uporabe
CN112585164A (zh) * 2018-04-12 2021-03-30 免疫医疗有限公司 用于治疗癌症的、lif抑制剂和pd-1轴抑制剂的组合
CN112384166A (zh) 2018-05-10 2021-02-19 网络牙科(美国)公司 自动牙钻
WO2019220204A2 (en) * 2018-05-14 2019-11-21 Mosaic Biomedicals Slu Antibodies against lif and dosage forms thereof
SG11202012576QA (en) * 2018-06-18 2021-01-28 Medimmune Ltd Combination of lif inhibitors and platinum-based antineoplastic agents for use in treating cancer
JP7770924B2 (ja) * 2019-04-24 2025-11-17 メモリアル スローン ケタリング キャンサー センター Ｒａｓ変異体癌を治療するための組成物および方法
WO2022051516A1 (en) 2020-09-03 2022-03-10 Cyberdontics (Usa), Inc. Method and apparatus for cna analysis of tooth anatomy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2363358B1 (es) * 2009-04-03 2012-06-21 FUNDACIÓ INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL D'HEBRON (Titular al Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable.
EP2371860A1 (en) * 2010-04-05 2011-10-05 Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
US9617336B2 (en) * 2012-02-01 2017-04-11 Compugen Ltd C10RF32 antibodies, and uses thereof for treatment of cancer
US20160237158A1 (en) * 2013-09-23 2016-08-18 Institut National De La Santé Et Da La Recherche Médicale (Inserm) Methods and Compositions for Targeting Tumor Microenvironment and for preventing Metastasis

Also Published As

Publication number Publication date
EP3191129A4 (en) 2018-03-14
CA2958685A1 (en) 2016-03-17
CN106687134A (zh) 2017-05-17
JP2017527582A (ja) 2017-09-21
US20170247446A1 (en) 2017-08-31
EP3191129A1 (en) 2017-07-19
WO2016040657A1 (en) 2016-03-17

Similar Documents

Publication Publication Date Title
US20170247446A1 (en) TARGETING K-RAS-MEDIATED SIGNALING PATHWAYS AND MALIGNANCY BY ANTI-hLIF ANTIBODIES
US9371568B2 (en) Markers associated with human double minute 2 inhibitors
US20130042333A1 (en) Markers for cancer prognosis and therapy and methods of use
EP2686441B1 (en) Methods and uses for predicting response to eribulin
ES3005230T3 (en) Diagnostic and therapeutic methods for the treatment of rheumatoid arthritis (ra)
US20210363593A1 (en) CXCL13 Marker For Predicting Immunotherapeutic Responsiveness In Patient With Lung Cancer And Use Thereof
US20120015049A1 (en) Microrna biomarker in cancer
US20220002396A1 (en) Methods of treating cancer with farnesyltransferase inhibitors
JP2016515141A (ja) 抗ｅｇｆｒ薬を用いた胃癌の処置のための、ｅｇｆｒバイオマーカーの使用
US20220249660A1 (en) Compositions and methods for treating lung, colorectal and breast cancer
EP2169077A1 (en) Methods and compositions for diagnosing an adenocarcinoma
US20110151469A1 (en) Interferon epsilon (ifne1) as a marker for targeted cancer therapy
US20170003292A1 (en) Paxip1 as a biomarker for wee1 inhibitor therapy
KR102800733B1 (ko) 담도암의 예방 또는 치료용 조성물
US20250002918A1 (en) Compositions and methods for treatment of mic60 depleted cancers and metastasis
KR102326119B1 (ko) 암의 면역 치료 후 예후 예측용 바이오 마커
CN118166100A (zh) Cd39作为胆管癌转移预测的诊断标记物和治疗靶点的用途
KR20240009911A (ko) Her2 양성 유방암 치료 예후 예측용 신규 바이오마커 및 이의 용도
O'Leary A Demethylation Screen Identifies Novel Targets of Epigenetic Regulation in Lung Cancer
HK1256118A1 (en) Fgfr expression and susceptibility to an fgfr inhibitor
HK1256118B (en) Fgfr expression and susceptibility to an fgfr inhibitor

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application